Showing 7581-7590 of 8693 results for "".
- Study Highlights Dermatology Resident Views on Sensitive Skin Educationhttps://practicaldermatology.com/news/study-highlights-dermatology-resident-views-sensitive-skin-education/2462717/In a recent article published in the Journal of Drugs in Dermatology, researchers shed light on the educational exposure and perspectives of dermatology resident physicians regarding sensitive skin. Sensitive skin, typified by symptoms such as redness, itching, burning, and sting
- Palm Phytonutrients To Be Displayed at Expohttps://practicaldermatology.com/news/palm-phytonutrients-be-displayed-expo/2462663/As the cosmeceutical market continues to expand, so does consumer interest in learning more about the key active ingredients in cosmeceutical products and how they work, according to a press release from palm phytonutrient manufacturer PhytoGaia. PhytoGaia, a manufacturer of palm phytonut
- Deucravacitinib Improves Patient-Reported Outcomes for Psoriatic Arthritishttps://practicaldermatology.com/news/deucravacitinib-improves-patient-reported-outcomes-psoriatic-arthritis/2462540/Deucravacitinib, a TYK-2 inhibitor, was linked with significant improvements in patient-reported outcomes (PROs) in patients with active psoriatic arthritis (PsA), according to results from a phase 2 trial. To assess the effects of deucravacitinib in this patient population, the study aut
- Study: Pembrolizumab Shows Efficacy in Japanese Patients with Advanced Melanomahttps://practicaldermatology.com/news/study-pembrolizumab-shows-efficacy-japanese-patients-advanced-melanoma/2462539/A recent analysis of the phase 1b KEYNOTE-041 trial indicated effectiveness and tolerability of pembrolizumab in Japanese patients with advanced melanoma. Researchers conducted the study over a 12-month period. The study evaluated pembrolizumab's long-term efficacy and safety in individua
- LEO Foundation Plans to Double Philanthropic Grants for Skin Diseaseshttps://practicaldermatology.com/news/leo-foundation-plans-double-philanthropic-grants-skin-diseases/2462483/Reporting a successful year in 2023, the LEO Foundation has announced its goals and aspirations out to 2030, including the awarding of a prestigious 5 million Danish kroner prize to a distinguished researcher in Denmark contributing to skin research. The Foundation plans to double its phi
- Probiotics Top List of Acne Supplement Ingredientshttps://practicaldermatology.com/news/probiotics-top-list-acne-supplement-ingredients/2462477/The most popular dietary supplements for acne contain probiotics, diindolylmethane, vitamin A, vitamin B complex, and zinc, according to a review of 13 supplements. Although surveys have shown that many acne patients opt for dietary supplements as adjunctive treatments, these products are
- American Acne and Rosacea Society (AARS) Releases Response to FDA Citizen's Petition from Valisurehttps://practicaldermatology.com/news/aars-releases-response-to-citizens-petition/2462445/The American Acne and Rosacea Society (AARS) has issued a public response to a recent report from Valisure showing common acne prod
- Oxidative Stress Linked with Acne Severity: Analysishttps://practicaldermatology.com/news/circulating-biomarkers-of-oxidative-stress-in-acne-vulgaris/2462438/Biomarkers of oxidative stress correlated with the severity of acne vulgaris, according to a recent review published in the Archives of Dermatological Research. "The relationship between acne vulgaris and oxidative stress biomarkers lacks a clear consensus," the authors wrote. "
- After Positive Phase 1 Results, Apogee to Test Twice-Yearly Dosing of Atopic Dermatitis Drug Candidatehttps://practicaldermatology.com/news/after-positive-phase-1-results-apogee-to-test-twice-yearly-dosing-of-atopic-dermatitis-drug-candidate/2462261/Apogee Therapeutics announced positive interim phase 1 data from its first-in-human study of APG777, one of its lead product candidates being developed as a frontline treatment for moderate-to-severe atopic dermatitis (AD) and other inflammatory diseases. Pharmacokinetic (PK) data showed a half-l
- Study: Test Improves the Risk Stratification of Patients with Stage I Melanomahttps://practicaldermatology.com/news/study-finds-decisiondx-melanoma-significantly-improves-the-risk-stratification-of-patients-with-stage-i-melanoma-compared-to-american-joint-committee-on-cancer-8th-edition-staging/2462252/Results from a recent study showed the potential of a 31-gene expression profile (31-GEP) test in improving the prognosis for patients diagnosed with stage I cutaneous melanoma. Despite being considered at low risk for metastasis or melanoma-specific death, patients with stage I cutaneous